Skip to content

Study Evaluating GAP-486 in Heart Rhythm

A Study to Characterize the Acute Electrophysiologic Properties, Safety and Tolerability of GAP-486

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00137293
Enrollment
30
Registered
2005-08-29
Start date
2005-11-30
Completion date
2006-10-31
Last updated
2007-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmia

Keywords

Arrhythmia, syncope, antiarrhythmic

Brief summary

The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.

Interventions

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing an electrophysiology study for evaluation of heart rhythm.

Exclusion criteria

* Patients with uncontrolled blood pressure * Patients with certain cardiac risk factors * Patients with significant kidney or liver problems

Design outcomes

Primary

MeasureTime frame
This study takes place within 24 hours. The measure to determine the effect of the intervention will be the difference in values from the baseline electrophysiology study, and the values obtained after intervention within the test drug.

Secondary

MeasureTime frame
This study takes place within 24 hours, and looks at the changes in values of electrophysiology studies, before and after administration of test article.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026